Please provide your email address to receive an email when new articles are posted on . Intravenous golimumab for JIA maintained an acceptable risk-benefit profile in a long-term extension study. The ...
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback